Not all drugs are incredible—and sometimes even the incredible ones have weird origins.
The FIP awards honored two international pharmacy associations for their recent campaigns.
EpiPen manufacturer is accused of lax investigation into problems.
After trials halted, FDA issues warning on off-label use of the drug.
After Mylotarg was taken voluntarily taken off the market, the FDA is giving it a second chance.
A petition sent by multiple groups says yes.
The Arizona Attorney’s General Office alleges that Insys made millions off illegal schemes.
In the midst of unprecedented disaster, pharmacists and pharmacies were prepared.
Why the agency says the approval of Novartis’ new therapy is historic.
The recall is just the latest in a bacterial contamination scare.